

Instituto de Salud Pública



Gobierno de Chile

Starting the reliance pathway for biological products The ISP Chile experience

30JAN2025

José Crisóstomo Landeros


Head of marketing authorization for biological products ANAMED ISP Chile


Disclaimers

- The views expressed in this presentation do not convey official ISP Chile policy or opinions.
- The information in this presentation relates to biological products and the pilot plan of reliance launched during October 2024.

Outline of the session

- ✓ ISP Chile.
- \checkmark Evolution of biological products evaluation in Chile.
- \checkmark The biological products team right now.
- ✓ Challenges.
- $\checkmark~$ The current legislation in Chile.
- \checkmark The reliance pilot plan.






Evolution of biologics through time

- \checkmark In the 80's there was no specific regulation about biologics.
- \checkmark In the 90's the D.S. 1876/95 define biological products.
- ✓ Our current legislation (D.S. 3/10) classified different biological products and biotherapeutics.
- ✓ During 2014 a specific regulatory framework for marketing authorization was created.
- ✓ After two years the biologics team was created, driven by PAHO recommendation.
- ✓ In 2020 we created a full biologics team, including the CMC, safety and efficacy review.

Team of marketing authorization for biological products

- 4 reviewers of safety and efficacy
- ➢ 6 reviewers of CMC
- In charge of the evaluation of all products considerer biologicals in Chile: Vaccines, monoclonal antibodies, blood products, proteins, antibiotics, and gene therapy products*




*The legislation in Chile do not include advance therapies yet, gene therapy is the only one included

Functions of the team

Marketing authorization.
 Post-approval changes
 Exceptional authorizations
 Other functions






The problems we are facing

- □ Huge delay in the review of marketing authorization.
- Currently, we are not capable of reviewing the number of products that enter every year.
- Stressed work environment due to this delay
- Other functions of the unit are also experienced delay





Reasons for the delay

Not enough staff

• The number of biological products that come in cannot be evaluated by the team (by the law we have 6 months for all types of products)



Pandemic

Review of COVID-19 vaccines



Products complexification

 Advanced therapies, ADC, bispecific antibodies, inmunocheckpoint, etc.



-) Low salaries at ISP compared with industry
 - Migration of trained colleagues

One of the possible solutions: RELIANCE

WHO Good Reliance Practices

World Health Organization

The act whereby the regulatory authority in one jurisdiction takes into account and gives significant weight to assessments performed by another regulatory authority or trusted institution, or to any other authoritative information in reaching its own decision.



- Importance of international cooperation to ensure the safety, quality and efficacy/performance of locally used medical products
- Make best use of available resources and expertise, avoid duplication and concentrate regulatory efforts and
 resources where most needed


Which authority do we considered first



 In 2022 they published RDC
 750 which established a temporary optimized review.

□ Not applicable for:

- Vaccines
- Biological products with clinical trials phase 2 or with not completed phase 3.
- During July 2024, this method was derogated by the RDC 886.





We had to keep looking









		etween these regulat	ory agencies			
Applicability						
Parameters	HSA, Singapore	TGA, Australia	MHRA, United Kingdome			
Reliance method	Verification	COR A: < 1-year post-approval reference NRA COR B	A: application submitted up to 2 years post-approval by NRA of reference.			
			B: application submitted up to 10 years post-approval by NRA of reference.			
Applicability:	 New product application Complete approval, not conditional. 	 New product, biotherapeutics, and biosimilar Complete approval, not conditional. 	 Biotherapeutics and biosimilars approved by the reference NRA. Complete approval, not conditional. 			
Not considered:	 Vaccines Withdrawn or cancelled products. 	•Product whose application was delayed, deferred, rejected, denied or withdrawn in any of the countries where it is registered.	 Products approved by reliance or recognition Products approved by emergency authorization. Withdrawn or cancelled products. 			

Departamento Agencia Nacional de Medicamentos (ANAMED)

	lr	nformation requested				
Parameters	HSA, Singapore	TGA, Australia	MHRA, United Kingdome			
References NRAs	Health Canada, TGA, PMDA, HSA , Swissmedic, MHRA, FDA, EMA					
Information to be presented	CTD format, modules 1 to 4; the same evaluated by the reference NRA. Questions and reports generated by the reference agency Reports of post-approval changes Official approval letter Public domain reports are not accepted.					
		•COR-A: 120 business days.	•Admissibility= 14 days			

- 1. CTD format, modules 1 to 4; the same evaluated by the reference NRA.
- 2. Questions and reports generated by the reference agency
- 3. Reports on post-approval changes
- 4. Official approval letter
- 5. Public domain reports are not accepted.
- 1. We are proposing the creation of 3 groups (1, 2 and 3), based on the time of the approval in the reference NRA:
- 2. Group 1: Full reliance
- 3. Group 2: Verification
- 4. Group 3: Normal review



- ✓ The need for implementation of mechanisms to diminish review times of medicines (especially biologics) by small NRAs.
- ✓ Reliance cannot be used for all products.
- Explore and advance in different pathways such as conditional approval or rolling review
- Communication and support between NRAs of our region, and around the world.
- ✓ The need for training of regulators because of the increase of complex products such as cell and gene therapies.

ACKNOWLEDGEMENTS

Biological team:

- Yanet Hechavarría
- Daniela Vásquez
- Cristina Troncoso
- Víctor Cortés
- Francisco Bori
- Valentina Salas
- Andrea Pando
- Fabiola Muñoz
- Viviana García
- Jaqueline Campos





Chile tiene al ISP

 $\widehat{}$

Thank you!